Genetic-guided therapy for newly diagnosed acute myeloid leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This study tests whether using a genetic profile of your leukemia plus a very sensitive test for leftover cancer cells can guide a more personalized treatment plan. The goal is to give you the most effective therapy while avoiding unnecessary side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 59 years old.
- You have just been diagnosed with acute myeloid leukemia (AML), a cancer of the blood and bone marrow.
- You have not had any prior treatment for AML, except possibly low-dose chemotherapy to control your blood counts.
- Your overall health is good (ECOG performance status 0-2), meaning you can do most daily activities.
- Your heart is functioning normally (with an ejection fraction of 50% or more) and you do not have serious heart disease.
- Your liver and kidney function tests are within safe ranges, and you have no active infections like HIV, syphilis, hepatitis B or C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adjusting chemotherapy based on early signs of leukemia can improve outcomes for people newly diagnosed with acute myeloid leukemia (AML). It might be a good fit if you are starting treatment and have a certain level of leukemia cells in your blood after a few days of therapy.
This trial compares two different strengths of a chemotherapy regimen that includes venetoclax (a targeted pill) for people with newly diagnosed acute myeloid leukemia (AML). The goal is to find which dose works as well or better with fewer side effects, and it may offer a more personalized treatment option for those who can tolerate intensive therapy.
This trial tests adding venetoclax (a targeted pill) to strong chemotherapy for people with newly diagnosed AML. It is for those whose leukemia cells do not clear quickly enough after standard induction therapy, to see if the combination helps them achieve remission.
This trial tests whether one initial chemotherapy approach works better than another in people newly diagnosed with high-risk acute myeloid leukemia (AML). You may benefit if your disease is high-risk, and the study will also compare how well the treatments control the leukemia and how safely they work.
This trial tests whether adding the targeted drug venetoclax to intensive chemotherapy works better for different types of AML. It is for people aged 14 to 60 who are newly diagnosed and have not received prior treatment.
This study tests a combination of two drugs (MDCyta and venetoclax) after an initial treatment to see if it helps people with newly diagnosed AML stay in remission. It is for adults aged 18 to 60 who are otherwise fairly healthy.
Hear when a new Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.